Article(id=1329869619231305731, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.02.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1673798400000, receivedDateStr=2023-01-16, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794995225007, onlineDateStr=2026-11-18, pubDate=1675958400000, pubDateStr=2023-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794995225007, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794995225007, creator=13701087609, updateTime=1794995225007, updator=13701087609, issue=Issue{id=1329869572141855203, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='2', pageStart='105', pageEnd='196', issueExtLink='null', onlineDate='null', pubDate='1675958400000', pubDateStr='2023-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794995213780, creator='13701087609', updateTime=1794995798529, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329872025146995085, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329872025146995086, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=113, endPage=116, ext={EN=ArticleExt(id=1329869619474575365, articleId=1329869619231305731, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Bispecific antibody drugs targeting PD-L1 progress in clinical research, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Bispecific antibody is an artificial antibody prepared by cell fusion or recombinant DNA technology that can specifically bind two antigens or two different epitopes of the same antigen at the same time. Immune checkpoint inhibitors have revolutionized the treatment paradigm for advanced solid tumors. However, not all types of malignancies respond to these drugs, and the response rate and treatment effect of cancer patients still need to be improved. This article reviewed the current status and progress of clinical research on dual-antibody drugs targeting programmed death ligand 1.

, authors=Ziwen DING, Yantong HE, Yan REN, Jiayun WU, Shuai YAO, Junlong WANG*, Na NI*, authorsList=Ziwen DING, Yantong HE, Yan REN, Jiayun WU, Shuai YAO, Junlong WANG, Na NI, authorCompany=null, correspAuthors=Junlong WANG, Na NI, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329869619705262087, articleId=1329869619231305731, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=以PD-L1为靶点的双特异性抗体药物临床研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

双特异性抗体是通过细胞融合或重组DNA技术制备的人工抗体,可以同时特异性结合两种抗原或同一抗原的两个不同表位。免疫检查点抑制剂彻底改变了晚期实体瘤的治疗模式。然而,并非所有类型的恶性肿瘤都对这些药物有反应,恶性肿瘤患者的响应率和治疗效果仍待提高。该文围绕以程序性死亡配体1为靶点的双抗药物的临床研究现状及进展作一综述。

, authors=丁子文, 何颜彤, 任燕, 吴嘉韵, 姚帅, 王俊龙*, 倪娜*, authorsList=丁子文, 何颜彤, 任燕, 吴嘉韵, 姚帅, 王俊龙, 倪娜, authorCompany=null, correspAuthors=王俊龙, 倪娜, authorNote=

丁子文,硕士研究生,研究方向:临床药学。

, correspAuthorsNote=
王俊龙,工程师,研究方向:创新药物的临床研究。
倪娜,副研究员,研究方向:创新药物的临床研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=FOh9yavZRq3PrxnOOmqXWA==, magXml=KaneGwfSgVxhRNxl5X+71w==, pdfUrl=null, pdf=VY7gj9ZILdFWAD8pyowDJg==, pdfFileSize=1514857, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=mde9EvBxF9YLGjPSO/DmVg==, mapNumber=null, fund=null)}, authors=[Author(id=1329869619977891853, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869620057583631, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869619977891853, language=EN, stringName=Ziwen DING, firstName=Ziwen, middleName=null, lastName=DING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869620120498192, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869619977891853, language=CN, stringName=丁子文, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院临床研究中心,上海 200437, bio={"content":"

丁子文,硕士研究生,研究方向:临床药学。

"}, bioImg=null, bioContent=

丁子文,硕士研究生,研究方向:临床药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869620191801362, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869620254715924, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620191801362, language=EN, stringName=Yantong HE, firstName=Yantong, middleName=null, lastName=HE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869620317630485, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620191801362, language=CN, stringName=何颜彤, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869620388933655, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869620460236825, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620388933655, language=EN, stringName=Yan REN, firstName=Yan, middleName=null, lastName=REN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869620523151386, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620388933655, language=CN, stringName=任燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869620581871644, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869620657369119, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620581871644, language=EN, stringName=Jiayun WU, firstName=Jiayun, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869620711895072, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620581871644, language=CN, stringName=吴嘉韵, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869620779003938, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869620850307109, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620779003938, language=EN, stringName=Shuai YAO, firstName=Shuai, middleName=null, lastName=YAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869620929998886, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620779003938, language=CN, stringName=姚帅, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869620997107752, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869621085188138, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620997107752, language=EN, stringName=Junlong WANG, firstName=Junlong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869621152297003, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620997107752, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869621223600173, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=6, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869621311680559, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869621223600173, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869621408149552, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869621223600173, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])])], keywords=[Keyword(id=1329869621542367281, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, language=EN, orderNo=1, keyword=PD-L1), Keyword(id=1329869621609476146, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, language=EN, orderNo=2, keyword=bispecific antibodies), Keyword(id=1329869621693362227, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, language=EN, orderNo=3, keyword=research progress), Keyword(id=1329869621756276788, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, language=CN, orderNo=1, keyword=程序性死亡配体1), Keyword(id=1329869621810802741, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, language=CN, orderNo=2, keyword=双特异性抗体), Keyword(id=1329869621882105911, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, language=CN, orderNo=3, keyword=研究进展)], refs=[Reference(id=1329869621995352120, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Labrijn AF, Janmaat ML, Reichert JM, et al. Bispecific antibodies: a mechanistic review of the pipeline[J]. Nat Rev Drug Discov, 2019, 18(8): 585-608., articleTitle=null, refAbstract=null), Reference(id=1329869622062460986, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Strauss J, Madan RA, Gulley JL. Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors[J]. Expert Opin Biol Ther, 2016, 16(7): 895-901., articleTitle=null, refAbstract=null), Reference(id=1329869622137958459, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Horn L, Mansfeld AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23): 2220-2229., articleTitle=null, refAbstract=null), Reference(id=1329869622200873020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors[J]. J Clin Oncol, 2018, 36(16): 1611-1618., articleTitle=null, refAbstract=null), Reference(id=1329869622280564797, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Lee SJ, Yang H, Kim WR, et al. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer[J]. J Immunother Cancer, 2021, 9(6): e002195., articleTitle=null, refAbstract=null), Reference(id=1329869622356062270, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients[J]. Science, 2021, 371(6529): 595-602., articleTitle=null, refAbstract=null), Reference(id=1329869622423171135, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Ott PA, Hu-Lieskovan S, Chmielowski B, et al. A phase Ⅰb trial of personalized neoantigen therapy plus anti PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer[J]. Cell, 2020, 183(2): 347-362., articleTitle=null, refAbstract=null), Reference(id=1329869622481891392, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Melero I, Berman DM, Aznar MA, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer[J]. Nat Rev Cancer, 2015, 15(8): 457-472., articleTitle=null, refAbstract=null), Reference(id=1329869622561583169, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Li JY, Perry SR, Muniz-Medina V, et al. A biparatopic HER2-targeting antibody drug conjugate induces tumor regressionin primary models refractory to or ineligible for HER2-targeted therapy[J]. Cancer Cell, 2016, 35(6): 948-949., articleTitle=null, refAbstract=null), Reference(id=1329869622628692034, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Kontermann RE. Dual targeting strategies with bispecific antibodies[J]. MAbs, 2012, 4(2): 182-197., articleTitle=null, refAbstract=null), Reference(id=1329869622695800899, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=王璐瑶, 魏振华, 熊伟佳, 等. 双特异性抗体构建在肿瘤临床治疗中的应用[J]. 生物工程学报, 2021, 37(2): 513-529., articleTitle=null, refAbstract=null), Reference(id=1329869622762909764, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药监局药审中心. 国家药监局药审中心关于发布《双特异性抗体抗肿瘤药物临床研发技术指导原则》的通告(2022年第40号)[EB/OL]. (2022-11-14) [2023-01-10]. https://www.cde.org.cn/main/news/viewInfoCommon/e9e97adf7fd91fff6c49afac1320d233., articleTitle=null, refAbstract=null), Reference(id=1329869622825824325, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ⅰb study[J]. J Clin Oncol, 2017, 35(19): 2117-2124., articleTitle=null, refAbstract=null), Reference(id=1329869622892933191, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=U. S. Food & Drug Administration. FDA approve avelumab for urothelial carcinonma maintenance treatment[EB/OL]. (2020-07-01) [2023-01-10]. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment., articleTitle=null, refAbstract=null), Reference(id=1329869622960042056, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, singlegroup, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(10): 1374-1385., articleTitle=null, refAbstract=null), Reference(id=1329869623043928137, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Paz-Ares L, Kim TM, Vicente D, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial[J]. J Thorac Oncol, 2020, 15(7): 1210-1222., articleTitle=null, refAbstract=null), Reference(id=1329869623119425611, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550., articleTitle=null, refAbstract=null), Reference(id=1329869623186534476, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-265., articleTitle=null, refAbstract=null), Reference(id=1329869623253643341, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study[J]. Lancet Oncol, 2018, 19(11): 1468-1479., articleTitle=null, refAbstract=null), Reference(id=1329869623320752206, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030): 1837-1846., articleTitle=null, refAbstract=null), Reference(id=1329869623383666767, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial[J]. Lancet Oncol, 2015, 16(4): 375-384., articleTitle=null, refAbstract=null), Reference(id=1329869623459164240, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma[J]. N Engl J Med, 201, 372(21): 2006-2017., articleTitle=null, refAbstract=null), Reference(id=1329869623526273105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639., articleTitle=null, refAbstract=null), Reference(id=1329869623589187666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ⅰb KEYNOTE-012 expansion cohort[J]. J Clin Oncol, 2016, 34(32): 3838-3845., articleTitle=null, refAbstract=null), Reference(id=1329869623647907923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Tolcher AW, Berlin JD, Cosaert J, et al. A phase 1 study of anti-TGF-β receptor type-Ⅱ monoclonal antibody LY3022859 in patients with advanced solid tumors[J]. Cancer Chemother Pharmacol, 2017, 79(4): 673-680., articleTitle=null, refAbstract=null), Reference(id=1329869623723405396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhao Y, Chen G, Li X, et al. Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: an open-label, multi-center phase Ⅱ trial[J]. Ann Oncol, 2022, 33(Suppl 7): S1025-S1026., articleTitle=null, refAbstract=null), Reference(id=1329869623819874389, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Xu R, Zhao H, Wei X, et al. Phase Ⅰa dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors[J]. J Clin Oncol, 2020, 38(15 Suppl): 3062., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.02.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.02.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.02.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.02.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1675958400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
以PD-L1为靶点的双特异性抗体药物临床研究进展
丁子文 , 何颜彤 , 任燕 , 吴嘉韵 , 姚帅 , 王俊龙 * , 倪娜 *
世界临床药物 | 医药专论 2023,44(2): 113-116
收起
收藏切换
世界临床药物 |医药专论 2023 , 44 (2) : 113 -116
以PD-L1为靶点的双特异性抗体药物临床研究进展
全屏
[Author(id=1329869619977891853, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869620057583631, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869619977891853, language=EN, stringName=Ziwen DING, firstName=Ziwen, middleName=null, lastName=DING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869620120498192, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869619977891853, language=CN, stringName=丁子文, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院临床研究中心,上海 200437, bio={"content":"

丁子文,硕士研究生,研究方向:临床药学。

"}, bioImg=null, bioContent=

丁子文,硕士研究生,研究方向:临床药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869620191801362, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869620254715924, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620191801362, language=EN, stringName=Yantong HE, firstName=Yantong, middleName=null, lastName=HE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869620317630485, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620191801362, language=CN, stringName=何颜彤, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869620388933655, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869620460236825, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620388933655, language=EN, stringName=Yan REN, firstName=Yan, middleName=null, lastName=REN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869620523151386, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620388933655, language=CN, stringName=任燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869620581871644, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869620657369119, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620581871644, language=EN, stringName=Jiayun WU, firstName=Jiayun, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869620711895072, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620581871644, language=CN, stringName=吴嘉韵, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869620779003938, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869620850307109, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620779003938, language=EN, stringName=Shuai YAO, firstName=Shuai, middleName=null, lastName=YAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869620929998886, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620779003938, language=CN, stringName=姚帅, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869620997107752, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869621085188138, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620997107752, language=EN, stringName=Junlong WANG, firstName=Junlong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869621152297003, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869620997107752, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1329869621223600173, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, orderNo=6, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869621311680559, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869621223600173, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869621408149552, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, authorId=1329869621223600173, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869619889811465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, xref=null, ext=[AuthorCompanyExt(id=1329869619898200074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1329869619906588683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869619231305731, companyId=1329869619889811465, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院临床研究中心,上海 200437)])])]
丁子文, 何颜彤, 任燕, 吴嘉韵, 姚帅, 王俊龙*, 倪娜*
作者信息
  • 中国医药工业研究总院临床研究中心,上海 200437
通讯作者:
王俊龙,工程师,研究方向:创新药物的临床研究。
倪娜,副研究员,研究方向:创新药物的临床研究。
作者简介:

丁子文,硕士研究生,研究方向:临床药学。

Bispecific antibody drugs targeting PD-L1 progress in clinical research
Ziwen DING, Yantong HE, Yan REN, Jiayun WU, Shuai YAO, Junlong WANG*, Na NI*
Affiliations
  • Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
出版时间: 2023-02-10 doi: 10.13683/j.wph.2023.02.002
文章导航
收藏切换

双特异性抗体是通过细胞融合或重组DNA技术制备的人工抗体,可以同时特异性结合两种抗原或同一抗原的两个不同表位。免疫检查点抑制剂彻底改变了晚期实体瘤的治疗模式。然而,并非所有类型的恶性肿瘤都对这些药物有反应,恶性肿瘤患者的响应率和治疗效果仍待提高。该文围绕以程序性死亡配体1为靶点的双抗药物的临床研究现状及进展作一综述。

程序性死亡配体1  /  双特异性抗体  /  研究进展

Bispecific antibody is an artificial antibody prepared by cell fusion or recombinant DNA technology that can specifically bind two antigens or two different epitopes of the same antigen at the same time. Immune checkpoint inhibitors have revolutionized the treatment paradigm for advanced solid tumors. However, not all types of malignancies respond to these drugs, and the response rate and treatment effect of cancer patients still need to be improved. This article reviewed the current status and progress of clinical research on dual-antibody drugs targeting programmed death ligand 1.

PD-L1  /  bispecific antibodies  /  research progress
丁子文, 何颜彤, 任燕, 吴嘉韵, 姚帅, 王俊龙, 倪娜. 以PD-L1为靶点的双特异性抗体药物临床研究进展. 世界临床药物, 2023 , 44 (2) : 113 -116 . DOI: 10.13683/j.wph.2023.02.002
Ziwen DING, Yantong HE, Yan REN, Jiayun WU, Shuai YAO, Junlong WANG, Na NI. Bispecific antibody drugs targeting PD-L1 progress in clinical research[J]. World Clinical Drug, 2023 , 44 (2) : 113 -116 . DOI: 10.13683/j.wph.2023.02.002

参考文献 引证文献
排序方式:
[1]
Labrijn AF, Janmaat ML, Reichert JM, et al. Bispecific antibodies: a mechanistic review of the pipeline[J]. Nat Rev Drug Discov, 2019, 18(8): 585-608.
[2]
Strauss J, Madan RA, Gulley JL. Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors[J]. Expert Opin Biol Ther, 2016, 16(7): 895-901.
[3]
Horn L, Mansfeld AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23): 2220-2229.
[4]
Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors[J]. J Clin Oncol, 2018, 36(16): 1611-1618.
[5]
Lee SJ, Yang H, Kim WR, et al. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer[J]. J Immunother Cancer, 2021, 9(6): e002195.
[6]
Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients[J]. Science, 2021, 371(6529): 595-602.
[7]
Ott PA, Hu-Lieskovan S, Chmielowski B, et al. A phase Ⅰb trial of personalized neoantigen therapy plus anti PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer[J]. Cell, 2020, 183(2): 347-362.
[8]
Melero I, Berman DM, Aznar MA, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer[J]. Nat Rev Cancer, 2015, 15(8): 457-472.
[9]
Li JY, Perry SR, Muniz-Medina V, et al. A biparatopic HER2-targeting antibody drug conjugate induces tumor regressionin primary models refractory to or ineligible for HER2-targeted therapy[J]. Cancer Cell, 2016, 35(6): 948-949.
[10]
Kontermann RE. Dual targeting strategies with bispecific antibodies[J]. MAbs, 2012, 4(2): 182-197.
[11]
王璐瑶, 魏振华, 熊伟佳, 等. 双特异性抗体构建在肿瘤临床治疗中的应用[J]. 生物工程学报, 2021, 37(2): 513-529.
[12]
国家药监局药审中心. 国家药监局药审中心关于发布《双特异性抗体抗肿瘤药物临床研发技术指导原则》的通告(2022年第40号)[EB/OL]. (2022-11-14) [2023-01-10]. https://www.cde.org.cn/main/news/viewInfoCommon/e9e97adf7fd91fff6c49afac1320d233.
[13]
Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ⅰb study[J]. J Clin Oncol, 2017, 35(19): 2117-2124.
[14]
U. S. Food & Drug Administration. FDA approve avelumab for urothelial carcinonma maintenance treatment[EB/OL]. (2020-07-01) [2023-01-10]. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment.
[15]
Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, singlegroup, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(10): 1374-1385.
[16]
Paz-Ares L, Kim TM, Vicente D, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial[J]. J Thorac Oncol, 2020, 15(7): 1210-1222.
[17]
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550.
[18]
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-265.
[19]
Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study[J]. Lancet Oncol, 2018, 19(11): 1468-1479.
[20]
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030): 1837-1846.
[21]
Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial[J]. Lancet Oncol, 2015, 16(4): 375-384.
[22]
Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma[J]. N Engl J Med, 201, 372(21): 2006-2017.
[23]
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
[24]
Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ⅰb KEYNOTE-012 expansion cohort[J]. J Clin Oncol, 2016, 34(32): 3838-3845.
[25]
Tolcher AW, Berlin JD, Cosaert J, et al. A phase 1 study of anti-TGF-β receptor type-Ⅱ monoclonal antibody LY3022859 in patients with advanced solid tumors[J]. Cancer Chemother Pharmacol, 2017, 79(4): 673-680.
[26]
Zhao Y, Chen G, Li X, et al. Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: an open-label, multi-center phase Ⅱ trial[J]. Ann Oncol, 2022, 33(Suppl 7): S1025-S1026.
[27]
Xu R, Zhao H, Wei X, et al. Phase Ⅰa dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors[J]. J Clin Oncol, 2020, 38(15 Suppl): 3062.
2023年第44卷第2期
14
3
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.02.002
  • 接收时间:2023-01-16
  • 首发时间:2026-11-18
  • 出版时间:2023-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-01-16
基金
作者信息
    中国医药工业研究总院临床研究中心,上海 200437

通讯作者:

王俊龙,工程师,研究方向:创新药物的临床研究。
倪娜,副研究员,研究方向:创新药物的临床研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.02.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏